Lipum AB (publ), a Swedish biopharmaceutical company focusing on innovative treatments for chronic inflammatory diseases, presented positive findings from its first-in-human clinical trial of SOL-116 at the American College of Rheumatology (ACR) Annual Meeting 2024. SOL-116, a pioneering humanized monoclonal antibody developed by Lipum, specifically targets Bile Salt-Stimulated Lipase (BSSL), a protein linked to chronic [...]
Lipum AB (publ) has published the interim report Q3 for the period July-September 2024. Below is a summary, a complete report (only in Swedish) is available on the company's website. CEO Ola Sandborgh comments: “Time flies and suddenly autumn is here. But as you know, time flies when you have a lot to do and [...]
Lipum AB (publ) announces that the eighth and thus final patient with rheumatoid arthritis (RA) has been recruited and dosed with SOL-116 or placebo in the ongoing clinical phase 1 study. The drug candidate SOL-116 is a humanized antibody that will provide safer and more effective treatment of inflammatory diseases by blocking a previously overlooked [...]
Lipum AB (publ) recruits Peter Hovstadius as the new Chief Medical Officer (CMO). Peter Hovstadius is a specialist in clinical pharmacology with a PhD in drug development from Uppsala University. Peter Hovstadius has a long career in both the pharmaceutical industry and academia. He has previously been in leading positions such as Chief Medical Officer [...]
Lipum AB (publ), a clinical stage biopharmaceutical company developing the drug candidate SOL-116 focused on chronic inflammatory diseases, today announced its participation in the following upcoming events during the autumn of 2024. NLSDays | 18-19 September | MalmöBioEurope | 4-6 November | StockholmRedeye Autoinflammatory day | 20 November | StockholmBioStockSummit | 20-21 November| Lund"These meetings [...]
Lipum AB (publ) has published the interim report Q2 for the period January-June 2024. Below is a summary, a complete report (only in Swedish) is available on the company's website. CEO Ola Sandborgh comments: “It is with a smile on my lips, I look back to the first half of 2024 which has been filled [...]
Lipum AB (publ) received in August 2018 a M€ 2.2 / MSEK 23 grant from the European Commission innovation program Horizon 2020. The successful project was completed in February 2021. In June 2022 was an audit of the project and its associated costs initiated. Lipum has now received a preliminary report regarding the audit. According [...]
Lipum AB (publ) announces that the multiple dose part of the phase I clinical study is completed. Eight healthy subjects have received four doses 28 days apart of SOL-116 or placebo with 90 days follow up period after last dose. The drug candidate SOL-116 evaluated in the clinical study is a humanised antibody that shall [...]
Lipum AB (publ) has published the interim report Q1 for the period January-March 2024. Below is a summary, a complete report (only in Swedish) is available on the company's website. CEO Ola Sandborgh comments: “I can with pride look back to a fantastic start of a new year. We continue according to plan and will [...]
Lipum AB (publ) has signed an agreement with Flerie Invest AB including a loan commitment of SEK 20 million. The agreement which has been signed on market terms, enters into force on 1 June 2024, has a term of 12 months and runs without collateral. "We are in a very intense phase with the completion [...]